A Phase I/II, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9?Engineered T Cells CTX112 in Subjects With Relapsed or Refractory B Cell Malignancies

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT05643742

Study #:
STUDY00149450

Start Date:
May 26, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05643742

View Complete Trial Details & Eligibility at ClinicalTrials.gov